Our Strategy

We partner with entrepreneurs to create companies that have a significant impact on patients’ lives. Participating at all stages of development and across all sectors, we take a broad strategic approach to investing in life sciences.

Typical Investments

Investment size$15-$30m in total per company
OwnershipMajority or minority
GeographyPrimarily US and Europe
Holding period3-8 years
SectorsBiotherapeutics, small molecules, nucleic acid therapeutics, vaccines, specialty pharma, technologies, medical devices, diagnostics, instrumentation


Within the life sciences market we participate in a wide range of opportunities spanning therapeutics, medical devices, diagnostics, instrumentation and software. We invest in seed stage projects, technology platforms, preclinical and clinical assets as well as approved and marketed products. Supporting private and public companies, we aim to partner with the most innovative entrepreneurs to address significant unmet needs in healthcare.

Discover the Strategies

Covering programmes and companies at many different stages of development, our diverse strategies provide us with unusually broad insights into the key factors for success in biotechnology.

"Abingworth not only devised and executed a thorough diligence process, but as our lead Series A investor, galvanized a strong long-term investor syndicate. Through their expansive network, they also helped us secure the site of our new corporate headquarters in an intensely competitive real estate market."

Grant Pickering, President and CEO of SutroVax

"I have known and admired the Abingworth team for many years and have relished the opportunity to partner with them at Chiasma. Their unique combination of analytic insights and business judgment, deriving from their extensive real world operating experience, enables them to support management teams and portfolio companies in ways that set them apart from most venture firms."

Mark Leuchtenberger, President and CEO of Chiasma

"We view Abingworth as a true partner. We are always seeking what we term ‘smart money’. Abingworth’s solid financial wherewithal and exceptional real-life operational prowess, coupled with their broad resources network, makes them the epitome of smart money."

Hani Zeini, Founder and CEO of Sientra

"I have found Abingworth to be extremely supportive in positioning Paratek for success. In addition to providing finance and executive leadership, their deep knowledge of the sector and extensive network have proven to be invaluable in creating value for the company today and in the future."

Evan Loh, President of Paratek Pharmaceuticals

"Abingworth has been an incredible partner. Their real-world operating experience allows companies to execute at the highest levels. Gynesonics would not be where we are today without their tremendous support."

Chris Owens, CEO of Gynesonics